Abstract
The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1.0 and 1.3 mg/m2), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated survival analyses after prolonged follow-up (median >5 years). One- and 5-year survival rates were 82% and 32%, respectively, in the 1.0 mg/m 2 group (n = 28), and 81% and 45%, respectively, in the 1.3 mg/m 2 group (n = 26). Notable survival, response, and time-to-progression data suggest that a bortezomib starting dose of 1.3 mg/m2 is preferred. If bortezomib dose reduction is required, the 1.0 mg/m2 dose still offers patients a substantial survival benefit.
| Original language | English |
|---|---|
| Pages (from-to) | 537-540 |
| Number of pages | 4 |
| Journal | British Journal of Haematology |
| Volume | 143 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 2008 |
Keywords
- Bortezomib
- Multiple myeloma
- Refractory
- Relapsed
- Survival
Fingerprint
Dive into the research topics of 'Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver